Chronic kidney disease in children

Clinical Kidney Journal

Volumn 9, Issue 4, 2016, Pages 583-591

  Becherucci, Francesca ^a   Roperto, Rosa Maria ^a   Materassi, Marco ^a   Romagnani, Paola ^a,b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Chronic renal failure; Chronic renal insufficiency; CKD; ESRD; Paediatrics

Indexed keywords

ANEMIA; BONE DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CHILDHOOD DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; GROWTH DISORDER; HUMAN; HYPERTENSION; MULTICENTER STUDY (TOPIC); NEPHROLOGIST; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW;

EID: 84992043944     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ckj/sfw047     Document Type: Review

References (105)

1. Lysaght MJ. Maintenance dialysis population dynamics: current trends and long-term implications. J Am Soc Nephrol 2002; 13: 37-40
2. United States Renal Data System. USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases, 2013
3. Schaefer B, Wühl E. Educational paper: progression in chronic kidney disease and prevention strategies. Eur J Pediatr 2012; 171: 1579-1588
4. Schieppati A, Remuzzi G. Chronic renal diseases as a public health problem: epidemiology, social, and economic implications. Kidney Int Suppl 2005; 98: S7-S10
5. Brück K, Stel VS, Fraser S et al. Translational research in nephrology: chronic kidney disease prevention and public health. Clin Kidney J 2015; 8: 647-655
6. Kidney Disease: Improving Global Outcomes (KDiGO) CKD work group. KDiGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013; 3: 1-150
7. Kidney Disease: Improving Global Outcomes (KDiGO) Glomerulonephritis Work Group. KDiGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl 2012; 2: 139-274
8. Wong CS,Warady BA. Epidemiology, etiology, and course of chronic kidney disease in children. 2015, www.uptodate. com (February 2016, date last accessed)
9. Warady BA, Chadha V. Chronic kidney disease in children: the global perspective. Pediatr Nephrol 2007; 22: 1999-2009
10. Esbjörner E, Berg U, Hansson S. Epidemiology of chronic renal failure in children: a report from Sweden 1986-1994. Swedish Pediatric Nephrology Association. Pediatr Nephrol 1997; 11: 438
11. Harambat J, van Stralen KJ, Kim JJ et al. Epidemiology of chronic kidney disease in children. Pediatr Nephrol 2012; 27: 363-373
12. Ardissino G, Daccò V, Testa S et al. Epidemiology of chronic renal failure in children: data from the ItalKid project. Pediatrics 2003; 111 (4 Pt 1): e382
13. ESPN/ERA-EDTA registry. European registry for children on renal replacement therapy. www.espn-reg.org/index.jsp (February 2016, date last accessed)
14. NAPRTCS: 2008 Annual Report. Rockville, MD: EMMES, 2008
15. Saran R, Li Y, Robinson B et al. US Renal Data System 2014 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis 2015; 66 (1 Suppl 1): Svii, S1
16. Australia and New Zealand Dialysis and Transplant Registry. The 28th annual report. 2005 report-data to 2004. 2005. http://www.anzdata.org (February 2016, date last accessed)
17. Wong CJ, Moxey-Mims M, Jerry-Fluker J et al. CKiD (CKD in children) perspective cohort study: a review of current findings. Am J Kidney Dis 2012; 60: 1002-1011
18. Lagomarsimo E, Valenzuela A, Cavagnaro F et al. Chronic renal failure in pediatrics 1996. Chilean survey. Pediatr Nephrol 1999; 13: 288
19. U.S. renal data system, USRDS 2005. Annual data report: Atlas of end-stage renal disease in the United States, National Institutes of Health. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases, 2005
20. Baum M. Overview of chronic kidney disease in children. Curr Opin Pediatr 2010; 22: 158-160
21. Harambat J, Bonthuis M, van Stralen KJ et al. Adult height in patients with advanced CKD requiring renal replacement therapy during childhood. Clin JAmSoc Nephrol 2014; 9: 92-99
22. Coresh J, Astor BC, Greene T et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41: 1-12
23. De Vecchi AF, Dratwa M,Wiedmann ME. Healthcare systems and end-stage renal disease: an international review-costs and reimbursement of ESRD therapies. N Eng J Med 1999; 14: 31-41
24. Moosa MR, Kidd M. The dangers of rationing dialysis treatment: the dilemma facing a developing country. Kidney Int 2006; 70: 1107-1114
25. Hoy WE. Renal disease in Australian aboriginals. Med J Aust 1996; 165: 126
26. Vivante A, Hildebrandt F. Exploring the genetic basis of early-onset chronic kidney disease. Nat Rev Nephrol 2016; 12: 133-146
27. Smith JM, Stablein DM, Munoz R et al. Contributions of the Transplant Registry: The 2006 Annual Report of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS). Pediatr Transplant 2007; 11: 366-373
28. Cain JE, Di Giovanni V, Smeeton J et al. Genetics of renal hypoplasia: insights into the mechanisms controlling nephron endowment. Pediatr Res 2010; 68: 91-98
29. Becherucci F, Lazzeri E, Lasagni L et al. Renal progenitors and childhood: from development to disorders. Pediatr Nephrol 2014; 29: 711-719
30. Black MJ, Sutherland MR, Gubhaju L et al. When birth comes early: effects on nephrogenesis. Nephrology 2013; 18: 180
31. Schreuder MF. Safety in glomerular numbers. Pediatr Nephrol 2012; 27: 1881
32. Ding W, Cheung WW, Mak RH. Impact of obesity on kidney function and blood pressure in children. World J Nephrol 2015; 4: 223-229
33. Tullus K. Is there an obesity-related epidemic of CKD starting already in childhood? Nephrol Dial Transplant 2013; 28 (Suppl 4): iv114-iv116
34. Hattori S, Yosioka K, Honda M et al. The 1998 report of the Japanese National Registry data on pediatric end-stage renal disease patients. Pediatr Nephrol 2002; 17: 456-461
35. Devuyst O, Knoers NV, Remuzzi G et al. Rare inherited kidney diseases: challenges, opportunities, and perspectives. Lancet 2014; 383: 1844-1859
36. Hildebrandt F. Genetic kidney diseases. Lancet 2010; 375: 1287-1295
37. Gupta J, Kanetsky PA, Wuttke M et al. Genome-wide association studies in pediatric chronic kidney disease. Pediatr Nephrol 2015 (epub ahead of print)
38. Dummer PD, Limou S, Rosenberg AZ et al. APOL1 kidney disease risk variants: an evolving landscape. Semin Nephrol 2015; 35: 222-236
39. Genovese G, Friedman DJ, Ross MD et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010; 329: 841-845
40. Parsa A, Kao WH, Xie D et al. APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med 2013; 369: 2183-2196
41. Giglio S, Provenzano A, Mazzinghi B et al. Heterogeneous genetic alterations in sporadic nephrotic syndrome associate with resistance to immunosuppression. J Am Soc Nephrol 2015; 26: 230-236
42. Büscher AK, Beck BB, Melk A et al. Rapid response to cyclosporin A and favorable renal outcome in nongenetic versus genetic steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol 2014; 11: 245-253
43. Seikaly MG, Salhab N, Gipson D et al. Stature in children with chronic kidney disease: analysis of NAPRTCS database. Pediatr Nephrol 2006; 21: 793-799
44. Rodig NM, McDermott KC, SchneiderMFet al. Growth in children with chronic kidney disease: a report from the chronic kidney disease in children study. Pediatr Nephrol 2014; 29: 1987-1995
45. Rees L. Growth hormone therapy in children with CKD after more than two decades of practice. Pediatr Nephrol 2015 (epub ahead of print).
46. André JL, Bourquard R, Guillemin F et al. Final height in children with chronic renal failure who have not received growth hormone. Pediatr Nephrol 2003; 18: 685-691
47. Mekahli D, Shaw V, Ledermann SE et al. Long-termoutcome of infants with severe chronic kidney disease. Clin J Am Soc Nephrol 2010; 5: 10-17
48. Gat-Yablonski G, Phillip M. Nutritionally-induced catch-up growth. Nutrients 2015; 7: 517-551
49. Kraut JA, Madias NE. Consequences and therapy of the metabolic acidosis of chronic kidney disease. Pediatr Nephrol 2011; 26: 19-28
50. Farquharson C, Ahmed SF. Inflammation and linear bone growth: the inhibitory role of SOCS2 on GH/IGF-1 signalling. Pediatr Nephrol 2013; 28: 547-556
51. Sanchez CP, Salusky IB, Kuizon BD et al. Growth of long bones in renal failure: roles of hyperparathyroidism, growth hormone and calcitriol. Kidney Int 1998; 54: 1879-1887
52. Rees L, Mak RH. Nutrition and growth in children with chronic kidney disease. Nat Rev Nephrol 2011; 7: 615-623
53. Mak RH, Cheung W, Cone RD et al. Orexigenic and anorexigenic mechanisms in the control of nutrition in chronic kidney disease. Pediatr Nephrol 2005; 20: 427-431
54. Hodson EM, Willis NS, Craig JC. Growth hormone for children with chronic kidney disease. Cochrane Database Syst Rev 2012; 2: CD003264
55. Gil S, Vaiani E, Guercio G et al. Effectiveness of rhGH treatment on final height of renal-transplant recipients in childhood. Pediatr Nephrol 2012; 27: 1005-1009
56. Fine RN, Stablein D. Long-term use of recombinant human growth hormone in pediatric allograft recipients: a report of the NAPRTCS transplant registry. Pediatr Nephrol 2005; 20: 404-408
57. Mahan JD, Warady BA, Consensus Committee. Assessment and treatment of short stature in pediatric patients with chronic kidney disease: a consensus statement. Pediatr Nephrol 2006; 21: 917-930
58. Kidney Disease: Improving Global Outcomes (KDiGO) CKD-MBD Work Group. KDiGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 2009; 76 (Suppl 113): S1-S130
59. Wesseling-Perry K, Salusky IB. Chronic kidney disease: mineral and bone disorder in children. Semin Nephrol 2013; 33: 169-179
60. Wesseling-Perry K. Bone disease in pediatric chronic kidney disease. Pediatr Nephrol 2013; 28: 569-576
61. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 2013; 382: 339-352
62. Rees L, Shroff R. The demise of calcium-based phosphate binders-is this appropriate for children? Pediatr Nephrol 2015; 30: 2061-2071
63. Rees L, Azocar M, Borzych D et al. Growth in very young children undergoing chronic peritoneal dialysis. J Am Soc Nephrol 2011; 22: 2303-2312
64. Klaus G, Watson A, Edefonti A et al. Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines. Pediatr Nephrol 2006; 21: 151-159
65. Block GA, Spiegel DM, Ehrlich J et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68: 1815-1824
66. Di Iorio B, Molony D, Bell C et al. Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial. Am J Kidney Dis 2013; 62: 771-778
67. Mitsnefes MM, Kimball TR, Kartal J et al. Progression of left ventricular hypertrophy in children with early chronic kidney disease: 2-year follow-up study. J Pediatr 2006; 149: 671-675
68. Kurella Tamura M, Vittinghoff E, Yang J et al. Anemia and risk for cognitive decline in chronic kidney disease. BMC Nephrol 2016; 17: 13
69. Dahlinghaus EK, Neu AM, Atkinson MA et al. Hemoglobin level and risk of hospitalization and mortality in children on peritoneal dialysis. Pediatr Nephrol 2014; 29: 2387-2394
70. Gerson A, HwangW, Fiorenza J et al. Anemia and health-related quality of life in adolescents with chronic kidney disease. Am J Kidney Dis 2004; 44: 1017-1023
71. KDOQI: National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006; 47 (Suppl 3): S11-S145
72. Atkinson MA, Furth SL. Anemia in children with chronic kidney disease. Nat Rev Nephrol 2011; 7: 635-641
73. Keithi-Reddy SR, Singh AK. Hemoglobin target in chronic kidney disease: a pediatric perspective. Pediatr Nephrol 2009; 24: 431-434
74. Atkinson MA, Martz K, Warady BA et al. Risk for anemia in pediatric chronic kidney disease patients: a report of NAPRTCS. Pediatr Nephrol 2010; 25: 1699-1706
75. Ratcliffe LE, ThomasW, Glen J et al. Diagnosis and management of iron deficiency in CKD: a summary of the NICE guideline recommendations and their rationale. Am J Kidney Dis 2016; 67: 548-558
76. Fraenkel PG. Understanding anemia of chronic disease. Hematology Am Soc Hematol Educ Program 2015; 2015: 14-18
77. Goodnough LT, Nemeth E, Ganz T. Detection, evaluation, and management of iron-restricted erythropoiesis. Blood 2010; 116: 754-4761
78. Nangaku M, Eckardt KU. Pathogenesis of renal anemia. Semin Nephrol 2006; 26: 261-268
79. Warady BA, Silverstein DM. Management of anemia with erythropoietic-stimulating agents in children with chronic kidney disease. Pediatr Nephrol 2014; 29: 1493-1505
80. Boehm M. Early erythropoietin therapy is associated with improved growth in children with chronic kidney disease. Pediatr Nephrol 2007; 22: 1189-1193
81. Port RE, Mehls O. Erythropoietin dosing in children with chronic kidney disease: based on body size or on hemoglobin deficit? Pediatr Nephrol 2009; 24: 435-437
82. Port RE, Kiepe D, Van Guilder M et al. Recombinant human erythropoietin for the treatment of renal anaemia in children: no justification for bodyweight-adjusted dosage. Clin Pharmacokinet 2004; 43: 57-70
83. Uemura O, Hattori M, Hataya H et al. Pharmacokinetics of darbepoetin alfa after single, intravenous or subcutaneous administration in Japanese pediatric patients with chronic kidney disease. Clin Exp Nephrol 2014; 18: 932-938
84. Kalantar-Zadeh K, Kalantar-Zadeh K, Lee GH. The fascinating but deceptive ferritin: to measure it or not to measure it in chronic kidney disease? Clin J Am Soc Nephrol 2006; 1 (Suppl 1): S9-S18
85. Morgan HE, Holt RC, Jones CA et al. Intravenous iron treatment in paediatric chronic kidney disease patients not on erythropoietin. Pediatr Nephrol 2007; 22: 1963-1965
86. Albaramki J, Hodson EM, Craig JC et al. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst Rev 2012; 1: CD007857
87. Mitsnefes MM. Cardiovascular disease in children with chronic kidney disease. J Am Soc Nephrol 2012; 23: 578-585
88. Flynn JT, Mitsnefes M, Pierce C et al. Blood pressure in children with chronic kidney disease: a report from the Chronic Kidney Disease in Children study. Hypertension 2008; 52: 631-637
89. Mitsnefes M, Flynn J, Cohn S et al. Masked hypertension associates with left ventricular hypertrophy in children with CKD. J Am Soc Nephrol 2010; 21: 137
90. VanDeVoorde RG, Misnefes MM. Hypertension and CKD. Adv Chronic Kidney Dis 2011; 18: 355-361
91. HsuTW, Liu JS, Hung SC et al. Renoprotective effect of reninangiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia. JAMA Intern Med 2014; 174: 347-354
92. Wühl E, Trivelli A, Picca S et al. Strict blood-pressure control and progression of renal failure in children. N Engl J Med 2009; 361: 1639-1650
93. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003; 42: 1050-1065
94. Anavekar NS, Pfeffer MA. Cardiovascular risk in chronic kidney disease. Kidney Int Suppl 2004; 92: S11-S15
95. Shroff R, Dégi A, Kerti A et al. Cardiovascular risk assessment in children with chronic kidney disease. Pediatr Nephrol 2013; 28: 875-884
96. Safder O, Al sharif S, Kari JA. Pediatric CKD and cardiovascular disease. Cardiovasc Hematol Disord Drug Targets 2014; 14: 177-184
97. Kavey RE, Allada V, Daniels SR et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the InterdisciplinaryWorking Group on Quality of Care and Outcomes Research: endorsed by the American Academyof Pediatrics. Circulation 2006; 114: 2710-2738
98. Paoli S, Mitsnefes MM. Coronary artery calcification and cardiovascular disease in children with chronic kidney disease. Curr Opin Pediatr 2014; 26: 193-197
99. Lilien MR, Groothoff JW. Cardiovascular disease in children with CKD or ESRD. Nat Rev Nephrol 2009; 5: 229-235
100. Tripepi G, Mallamaci F, Zoccali C. Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. J Am Soc Nephrol 2005; 16 (Suppl 1): S83-S88
101. Briet M, Boutouyrie P, Laurent S et al. Arterial stiffness and pulse pressure in CKD and ESRD. Kidney Int 2012; 2: 388-400
102. Matteucci MC, Wühl E, Picca S et al. Left ventricular geometry in children with mild to moderate chronic renal insufficiency. J Am Soc Nephrol 2006; 17: 218-226
103. Matsushita K, Sang Y, Ballew SH et al. Subclinical atherosclerosis measures for cardiovascular prediction in CKD. J Am Soc Nephrol 2015; 26: 439-447
104. Yao Q, Pecoits-Filho R, Lindholm B et al. Traditional and non-traditional risk factors as contributors to atherosclerotic cardiovascular disease in end-stage renal disease. Scand J Urol Nephrol 2004; 38: 405-416
105. McDonald SP, Craig JC. Long-term survival of children with end-stage renal disease. N Engl J Med 2004; 350: 2654-2662